Current Ratio
Higher than 95% of Healthcare sector peers
Updated 22h ago
Sector Performance
95th percentileBEAM
16.99x
Sector Median
2.02x
Sector Avg
3.77x
Deep Analysis
The current ratio of 16.99x means Beam Therapeutics has nearly $17 of short-term assets for every $1 of short-term liabilities, indicating exceptional ability to cover upcoming debts.
This figure is far above the healthcare sector median of 2.02x, placing the company in the 95th percentile among its peers. Trend data is not available: both the year-over-year and quarter-over-quarter changes are reported as N/A, so no direction can be inferred. The extremely high level alone suggests low near-term liquidity risk, but without a trend, it is impossible to assess whether this strength is stable or temporary. This metric supports the overall NEUTRAL verdict — the high ratio reduces default risk, offering downside protection, yet does not signal the growth catalysts needed for a bullish stance.
Frequently Asked Questions
What does the Current Ratio tell investors about BEAM?
Measures short-term financial health. A ratio above 1.5 is generally healthy; below 1.0 may indicate liquidity stress.
How is the Current Ratio calculated?
Current Ratio is calculated as: Current Assets / Current Liabilities.
How does BEAM's Current Ratio compare to its sector?
BEAM's Current Ratio of 16.99x compares to a Healthcare sector median of 2.02x, placing it in the 95th percentile.
Who are BEAM's closest peers by Current Ratio?
The closest Healthcare peers by Current Ratio include: BAX (1.85x), ZBH (1.73x), RVTY (1.72x), HIMS (1.69x), TMO (1.53x).
The Formula
Current Assets / Current Liabilities
Why It Matters
Measures short-term financial health. A ratio above 1.5 is generally healthy; below 1.0 may indicate liquidity stress.
Master BEAM's Valuation
Get the complete institutional research report covering all fundamental and technical metrics.
View full BEAM research report →BEAM
16.99x
Sector Median
2.02x
Sector Avg
3.77x
How BEAM's Current Ratio compares to sector peers.
Also Analyze
Not financial advice. Research tool only. Data may be delayed.